Skip to main content

BG Medicine Nabs Commercial Rights to ACS Biomarker

NEW YORK (GenomeWeb News) – Massachusetts-based BG Medicine has acquired exclusive, worldwide rights from ACS Biomarker to develop and commercialize a clinical diagnostic test for acute atherothrombosis, the companies announced yesterday.
 
Scientists at the Cardiovascular Research Institute Maastricht in the Netherlands discovered the biomarker, which BG plans to develop into a test to diagnose transient blockages that cause stroke-like symptoms, coronary artery blockages, and other heart attack and stroke precursors.
 
In exchange for the license, ACS Biomarker will receive from BG milestone payments as well as royalties on net sales and sublicensing income on any commercialized products.
 
ACS Biomarker was founded to develop and commercialize cardiovascular biomarkers discovered at CARIM.  
 
Atherothrombosis results from ruptured arterial plaques, which send deposits hurtling through the arteries, where they can cause blood clotting and, ultimately, heart attacks or strokes. But the condition often goes unnoticed until it manifests itself as a life-threatening cardiovascular event.
 
The latest deal comes after a May 2007 agreement between the two companies in which BG Medicine acquired the rights to ACS Biomarker’s biomarker for congestive heart failure.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.